Evidence map›Paper›PMID 35893837›Full record

ArticleVaccines2022

Reduction in Rubella Virus Active Cases among Children and Adolescents after Rubella Vaccine Implementation in Tanzania: A Call for Sustained High Vaccination Coverage.

Fausta Michael, Mariam M Mirambo, Dafrossa Lyimo, Furaha Kyesi, Delfina R Msanga, Georgina Joachim, Honest Nyaki, Richard Magodi, Delphius Mujuni, Florian Tinuga and 12 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Vaccines, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.6field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 4 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors at 4 institutions in 2 countries.

Fausta MichaelMinistry of Health, Immunization and Vaccine Development Program, Dodoma P.O. Box 743, Tanzania.
Mariam M MiramboDepartment of Microbiology and Immunology, Weill Bugando School of Medicine, Catholic University of Health and Allied Sciences, Mwanza P.O. Box 1464, Tanzania.
Dafrossa LyimoMinistry of Health, Immunization and Vaccine Development Program, Dodoma P.O. Box 743, Tanzania.
Furaha KyesiMinistry of Health, Immunization and Vaccine Development Program, Dodoma P.O. Box 743, Tanzania.
Delfina R MsangaDepartment of Pediatrics and Child Health, Weill Bugando School of Medicine, Catholic University of Health and Allied Sciences, Mwanza P.O. Box 1464, Tanzania.ORCID 0000-0002-3472-9620
Georgina JoachimMinistry of Health, Immunization and Vaccine Development Program, Dodoma P.O. Box 743, Tanzania.
Honest NyakiMinistry of Health, Immunization and Vaccine Development Program, Dodoma P.O. Box 743, Tanzania.
Richard MagodiMinistry of Health, Immunization and Vaccine Development Program, Dodoma P.O. Box 743, Tanzania.
Delphius MujuniMinistry of Health, Immunization and Vaccine Development Program, Dodoma P.O. Box 743, Tanzania.
Florian TinugaMinistry of Health, Immunization and Vaccine Development Program, Dodoma P.O. Box 743, Tanzania.
Ngwegwe BululaMinistry of Health, Immunization and Vaccine Development Program, Dodoma P.O. Box 743, Tanzania.
Bonaventura NestoryMinistry of Health, Immunization and Vaccine Development Program, Dodoma P.O. Box 743, Tanzania.
Dhamira MongiMinistry of Health, Immunization and Vaccine Development Program, Dodoma P.O. Box 743, Tanzania.
Ahmed MakuwaniMinistry of Health, Immunization and Vaccine Development Program, Dodoma P.O. Box 743, Tanzania.
Betina KatemboNational Public Health Laboratory, Dar es Salaam P.O. Box 9083, Tanzania.
William MwengeeWorld Health Organization, Country Office, Dar es Salaam P.O. Box 9292, Tanzania.
Alex MphuruUnited Nations Children's Fund (UNICEF), Country Office, Dar es Salaam P.O. Box 4076, Tanzania.
Nassor MohamedImmunization Center, John Snow Inc. (JSI), 2733 Crystal Dr 4th Floor, Arlington, VA 22202, USA.ORCID 0000-0001-5813-4579
David KayabuManagement and Development for Health (MDH), Dar es Salaam P.O Box 79810, Tanzania.
Helmut NyawaleDepartment of Microbiology and Immunology, Weill Bugando School of Medicine, Catholic University of Health and Allied Sciences, Mwanza P.O. Box 1464, Tanzania.
Eveline T KonjeDepartment of Epidemiology and Biostatistics, School of Public Health, Catholic University of Health and Allied Sciences, Mwanza P.O. Box 1464, Tanzania.
Stephen E MshanaDepartment of Microbiology and Immunology, Weill Bugando School of Medicine, Catholic University of Health and Allied Sciences, Mwanza P.O. Box 1464, Tanzania.ORCID 0000-0002-7526-6271
Ministry of Health, Community Development, Gender, Elderly and Children · TZCatholic University of Health and Allied Sciences · TZJohn Snow (United States) · USManagement and Development for Health · TZ

Funding

World Health Organization 001
6 · The paper itself

Abstract

Rubella virus (RV) infection in susceptible women during the first trimester of pregnancy is associated with congenital Rubella syndrome (CRS). In countries where a vaccination program is implemented, active case surveillance is emphasized. This report documents the magnitude of active cases before and after vaccine implementation in Tanzania. A total of 8750 children and adolescents with signs and symptoms of RV infection were tested for Rubella IgM antibodies between 2013 and 2019 using enzyme immunoassay followed by descriptive analysis. The median age of participants was 3.8 (IQR: 2−6.4) years. About half (4867; 55.6%) of the participants were aged 1−5 years. The prevalence of RV active cases was 534 (32.6%, 95% CI: 30.2−34.9) and 219 (3.2%, 95% CI: 2.7−3.6) before and after vaccine implementation, respectively. Before vaccination, the highest prevalence was recorded in Pemba (78.6%) and the lowest was reported in Geita (15.6%), whereas, after vaccination, the prevalence ranged between 0.5% in Iringa and 6.5% in Pemba. Overall, >50% of the regions had a >90% reduction in active cases. The significant reduction in active cases after vaccine implementation in Tanzania underscores the need to sustain high vaccination coverage to prevent active infections and eventually eliminate CRS, which is the main goal of Rubella vaccine implementation.

Indexed as

active Rubella infectionCRSTanzaniavaccination

Identifiers

PMID35893837
PMCPMC9332844
OpenAlexW4288177368

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.